Conditions: Pulmonary Disease, Chronic Obstructive
Keywords: Safety Chronic Obstructive Pulmonary Disease Efficacy FEV1 COPD
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1031
Healthy volunteers: no

Brief summary:
The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subjects with chronic obstructive pulmonary disease (COPD)

Detailed description:

Arms:
arm 1: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) arm 2: Inhaled Corticosteroid (ICS) arm 3: Long Acting Beta Agonist(LABA) arm 4: Placebo arm 5: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)

Interventions: intervention 1: FF/GW642444 Inhalation Powder intervention 2: FF Inhalation Powder intervention 3: GW642444 Inhalation Powder intervention 4: Placebo
Intervention descriptions: intervention 1: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD intervention 2: Inhaled Corticosteroid (ICS) intervention 3: Long Acting Beta Agonist(LABA) intervention 4: Placebo

Protocol document: